| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Filing marks first NDA submission for any psychedelic-assisted therapy Submission represents 30 plus years of clinical research into potential use of MDMA-assisted therapy for PTSD NDA includes...
Study met primary and secondary endpoints confirming first Phase 3 study findings MAPP2 population reflects PTSD demographic with approximately half of study participants identifying as racially...
Codes will provide qualified healthcare professionals a means to seek reimbursement for delivering MDMA-assisted therapy if it is approved by the U.S. Food and Drug Administration SAN JOSE, Calif....
Agreement underscores benefit of collaboration to accelerate review of new evidence-based treatment options for people with PTSD Submission of new drug application expected in the second half of 2023
COMPASS Pathways and MAPS PBC submitted joint application for new code to facilitate access to psychedelic therapy in the US, if approved London, UK and San Jose, US – May 2, 2023 COMPASS...